Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadopiclenol vs gadoterate meglumine for pediatric cardiac MRI in congenital heart disease
2025-524029-41-00Phase 3Authorised
- Sponsor
- Fundació Sant Joan de Déu
- Start
- Feb 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gadopiclenol in Cardiomyopathies, tetralogy of Fallot (TOF) and Cardiovascular Malformation (CVM), sponsored by Fundació Sant Joan de Déu. Planned start Feb 2026; status: authorised.
02
Drugs
gadopiclenol
03
Conditions
Cardiomyopathiestetralogy of Fallot (TOF)Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on 2025-524029-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524029-41-00.